ARIAD Pharmaceuticals Inc historical data, for real-time data please try another search

ARIAD Pharmaceuticals Inc (ARIA)

NASDAQ
23.99
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    23.94/23.99
  • Day's Range:
    23.94 - 23.99

ARIA Overview

Prev. Close
23.99
Day's Range
23.94-23.99
Revenue
186.24M
Open
23.95
52 wk Range
-
EPS
-0.18
Volume
0
Market Cap
4.66B
Dividend (Yield)
0.00
(N/A)
Average Vol. (3m)
7,133,040
P/E Ratio
-
Beta
2.18
1-Year Change
0%
Shares Outstanding
194,200,862
Next Earnings Date
-
What is your sentiment on ARIAD Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

ARIAD Pharmaceuticals Inc News

ARIAD Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

ARIAD Pharmaceuticals Inc Company Profile

ARIAD Pharmaceuticals Inc Company Profile

Employees
459

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Read More
  • ''dentist'' came to Ariad to fix the hole. Now make a nice research treatment against cancer to return the favor.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.